OR WAIT null SECS
April 23, 2020
Bayer will provide CAD $1.5 million (USD$1 million) toward two studies to evaluate its chloroquine and interferon beta-1b combination therapies.
Wavelength Pharmaceuticals expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients in the COVID-19 pandemic.
Catalent Biologics increased capacity at its Bloomington, IN Facility.
April 22, 2020
The companies will collaborate on the discovery and development of next-generation drug and engineered cell therapies focused on natural killer cells.
April 21, 2020
The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.
April 20, 2020
The report outlines the company’s approaches to product quality, safety, environmental sustainability, and diversity and inclusion.
April 16, 2020
Medical dermatology company based in Denmark, Leo Pharma, has entered into a license agreement with two Eastern-Asian companies for the development and commercialization of FB825, a novel atopic dermatitis and allergic asthma drug candidate.
Dutch company HALIX has announced it is joining a consortium of partners that are all under the guidance of the University of Oxford to provide good manufacturing practice (GMP) manufacturing services for a COVID-19 vaccine.
Biopharmaceutical company, TScan Therapeutics, has entered into a collaboration agreement with Novartis that is aimed at the discovery and development of novel T-cell receptor (TCR) therapies for solid tumors.
This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.